Parnell Pharmaceuticals Holdings Ltd. reported unaudited consolidated earnings results for the nine months ended September 30, 2016. For the period, the company reported revenue was AUD 13,774,480 against AUD 8,490,393 a year ago. Loss before income tax was AUD 18,572,632 against AUD 5,415,738 a year ago. Loss for the period was AUD 18,583,557 or AUD 1.21 basic and diluted per share against AUD 5,417,851 or AUD 0.41 basic and diluted per share a year ago. Total comprehensive loss for the period was AUD 17,357,780 against AUD 8,129,723 a year ago.

For the remainder of 2016 and in to 2017, the company expects to see continued strong revenue growth from all three of Business Segments which The company anticipates will lead to Parnell returning to profitability in 2017.